Abstract
Janus kinases (JAKs) are a family of non-receptor tyrosine kinases, composed by four members, JAK1, JAK2, JAK3 and TYK2. JAKs are involved in different inflammatory and autoimmune diseases, as well as in malignancies, through the activation of the JAK/STAT signalling pathway. Furthermore, the V617F mutation in JAK2 was identified in patients affected by myeloproliferative neoplasms. This knowledge prompted researchers from academia and pharmaceutical companies to investigate this field in order to discover small molecule JAK inhibitors. These efforts recently afforded to the market approval of four JAK inhibitors. Despite the fact that all these drugs are pyrrolo[2,3-d]pyrimidine derivatives, many compounds endowed with different heterocyclic scaffolds have been reported in the literature as selective or multi-JAK inhibitors, and a number of them is currently being evaluated in clinical trials. In this review we will report many representative compounds that have been published in articles or patents in the last five years (period 2013-2017). The inhibitors will be classified on the basis of their chemical structure, focusing, when possible, on their structure activity relationships, selectivity and biological activity. For every class of derivatives, compounds disclosed before 2013 that have entered clinical trials will also be briefly reported, to underline the importance of a particular chemical scaffold in the search for new inhibitors.
Keywords: JAK inhibitors, patents, anticancer agents, inflammatory diseases, autoimmune diseases, heterocyclic compounds, covalent inhibitors.
[1]
Babon, J.J.; Lucet, I.S.; Murphy, J.M.; Nicola, N.A.; Varghese, L.N. The molecular regulation of Janus kinase (JAK) activation. Biochem. J., 2014, 462, 1-13.
[2]
Menet, C.J.; Mammoliti, O.; López-Ramos, M. Progress toward JAK1-selective inhibitors. Future Med. Chem., 2015, 7, 203-235.
[3]
Roskoski, R., Jr Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol. Res., 2016, 111, 784-803.
[4]
Yamaoka, K.; Saharinen, P.; Pesu, M.; Holt, V.E., III; Silvennoinen, O.; O’Shea, J.J. The Janus kinases (Jaks). Genome Biol., 2004, 5, 253.
[5]
Darnell, J.E., Jr; Kerr, I.M.; Stark, G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 1994, 264, 1415-1421.
[6]
Jones, A.V.; Kreil, S.; Zoi, K.; Waghorn, K.; Curtis, C.; Zhang, L.; Score, J.; Seear, R.; Chase, A.J.; Grand, F.H.; White, H.; Zoi, C.; Loukopoulos, D.; Terpos, E.; Vervessou, E.C.; Schultheis, B.; Emig, M.; Ernst, T.; Lengfelder, E.; Hehlmann, R.; Hochhaus, A.; Oscier, D.; Silver, R.T.; Reiter, A.; Cross, N.C. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, 2005, 106, 2162-2168.
[7]
Quintás-Cardama, A.; Verstovsek, S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin. Cancer Res., 2013, 19, 1933-1940.
[8]
Ghoreschi, K.; Laurence, A.; O’Shea, J.J. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat. Immunol., 2009, 10, 356-360.
[9]
Ghoreschi, K.; Gadina, M. Jakpot! New small molecules in autoimmune and inflammatory diseases. Exp. Dermatol., 2014, 23, 7-11.
[10]
Saeed, I.; McLornan, D.; Harrison, C.N. Managing side effects of JAK inhibitors for myelofibrosis in clinical practice. Expert Rev. Hematol., 2017, 10, 617-625.
[11]
Deisseroth, A.; Kaminskas, E.; Grillo, J.; Chen, W.; Saber, H.; Lu, H.L.; Rothmann, M.D.; Brar, S.; Wang, J.; Garnett, C.; Bullock, J.; Burke, L.B.; Rahman, A.; Sridhara, R.; Farrell, A.; Pazdur, R.U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin. Cancer Res., 2012, 18, 3212-3217.
[12]
Barosi, G.; Rosti, V.; Gale, R.P. Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis. OncoTargets Ther., 2015, 18, 1091-1102.
[13]
van Vollenhoven, R.F. Rheumatoid arthritis in 2012: Progress in RA genetics, pathology and therapy. Nat. Rev. Rheumatol., 2013, 9, 70-72.
[14]
Gonzales, A.J.; Bowman, J.W.; Fici, G.J.; Zhang, M.; Mann, D.W.; Mitton-Fry, M. Oclacitinib (APOQUEL(®)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J. Vet. Pharmacol. Ther., 2014, 37, 317-324.
[16]
Williams, N.K.; Bamert, R.S.; Patel, O.; Wang, C.; Walden, P.M.; Wilks, A.F.; Fantino, E.; Rossjohn, J.; Lucet, I.S. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J. Mol. Biol., 2009, 387, 219-232.
[17]
Musumeci, F.; Sanna, M.; Grossi, G.; Brullo, C.; Fallacara, A.L.; Schenone, S. Pyrrolo [2,3-d]pyrimidines as kinase inhibitors. Curr. Med. Chem., 2017, 24, 2059-2085.
[18]
Nerviano Medical Sciences, S.R.L. Substituted pyrroles as
kinase inhibitors and their preparation. WO 2014019908, 2014.
[19]
Nerviano Medical Sciences, S.R.L. Preparation of pyrimidinylpyrrole
derivatives for use as kinase inhibitors. WO
2012143248, 2012.
[20]
Brasca, M.G.; Nesi, M.; Avanzi, N.; Ballinari, D.; Bandiera, T.; Bertrand, J.; Bindi, S.; Canevari, G.; Carenzi, D.; Casero, D.; Ceriani, L.; Ciomei, M.; Cirla, A.; Colombo, M.; Cribioli, S.; Cristiani, C.; Della Vedova, F.; Fachin, G.; Fasolini, M.; Felder, E.R.; Galvani, A.; Isacchi, A.; Mirizzi, D.; Motto, I.; Panzeri, A.; Pesenti, E.; Vianello, P.; Gnocchi, P.; Donati, D. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors. Bioorg. Med. Chem., 2014, 22, 4998-5012.
[21]
Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole
carboxamides as Janus kinase inhibitors. WO 2013040863, 2013.
[22]
Merck Sharp & Dohme Corp. Pyrazole carboxamides as
Janus kinase inhibitors. WO 2013041042, 2013.
[23]
Merck Sharp & Dohme Corp. Cyanomethylpyrazole carboxamides
as Janus kinase inhibitors. WO 2013043962, 2013.
[24]
Merck Sharp & Dohme Corp. Acyclic cyanoethylpyrazoles
as Janus kinase inhibitors. WO 2013043964, 2013.
[25]
Incyte Corporation. Preparation of bipyrazole derivatives as
JAK kinase inhibitors. WO 2014186706, 2014.
[26]
Liang, X.; Huang, Y.; Zang, J.; Gao, Q.; Wang, B.; Xu, W.; Zhang, Y. Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors. Bioorg. Med. Chem., 2016, 24, 2660-2672.
[27]
Liang, X.; Zang, J.; Zhu, M.; Gao, Q.; Wang, B.; Xu, W.; Zhang, Y. Design, synthesis, and antitumor evaluation of 4-amino-(1H)-pyrazole derivatives as JAKs inhibitors. ACS Med. Chem. Lett., 2016, 7, 950-955.
[28]
Sang, Y-L.; Duan, Y-T.; Qiu, H-Y.; Wang, P-F.; Makawana, J.A.; Wang, Z-C.; Zhu, H-L.; He, Z-X. Design, synthesis, biological evaluation and molecular docking of novel metronidazole derivatives as selective and potent JAK3 inhibitors. RSC Advances, 2014, 4, 16694-16704.
[29]
Exelixis Inc. 4-Aryl-2-amino-pyrimidines or 4-aryl-2-
aminoalkyl-pyrimidines as JAK-2 modulators and methods
of use. WO 2007089768, 2007.
[32]
YM Biosciences Australia Pty Ltd. Preparation of phenyl
amino pyrimidine bicyclic compounds useful as protein
kinase inhibitors. WO 2014000032, 2014.
[33]
Calitor Sciences LLC, Sunshine Lake Pharma Co., Ltd.
Substituted heteroaryl compounds and methods of use. WO
2015094803, 2015.
[34]
Dana-Faber Cancer Institute, Inc. Janus kinase inhibitors
and uses thereof. WO 2015164614, 2015.
[35]
Joshi, M.; Rizvi, S.M.; Belani, C.P. Afatinib for the treatment of metastatic non-small cell lung cancer. Cancer Manag. Res., 2015, 7, 75-82.
[36]
de Claro, R.A.; McGinn, K.M.; Verdun, N.; Lee, S.L.; Chiu, H.J.; Saber, H.; Brower, M.E.; Chang, C.J.; Pfuma, E.; Habtemariam, B.; Bullock, J.; Wang, Y.; Nie, L.; Chen, X.H.; Lu, D.R.; Al-Hakim, A.; Kane, R.C.; Kaminskas, E.; Justice, R.; Farrell, A.T.; Pazdur, R. FDA approval: Ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin. Cancer Res., 2015, 21, 3586-3590.
[37]
Tan, L.; Akahane, K.; McNally, R.; Reyskens, K.M.; Ficarro, S.B.; Liu, S.; Herter-Sprie, G.S.; Koyama, S.; Pattison, M.J.; Labella, K.; Johannessen, L.; Akbay, E.A.; Wong, K.K.; Frank, D.A.; Marto, J.A.; Look, T.A.; Arthur, J.S.; Eck, M.J.; Gray, N.S. Development of selective covalent Janus kinase 3 inhibitors. J. Med. Chem., 2015, 58, 6589-6606.
[40]
Almirall, S.A. Preparation of 2-(pyrazolopyridin-3-yl)
pyrimidine derivatives as JAK inhibitors. WO 2016198663, 2016.
[42]
Vertex Pharmaceuticals Inc. Azaindoles useful as inhibitors
of Janus kinases. WO 2007084557, 2007.
[44]
Farmer, L.J.; Ledeboer, M.W.; Hoock, T.; Arnost, M.J.; Bethiel, R.S.; Bennani, Y.L.; Black, J.J.; Brummel, C.L.; Chakilam, A.; Dorsch, W.A.; Fan, B.; Cochran, J.E.; Halas, S.; Harrington, E.M.; Hogan, J.K.; Howe, D.; Huang, H.; Jacobs, D.H.; Laitinen, L.M.; Liao, S.; Mahajan, S.; Marone, V.; Martinez-Botella, G.; McCarthy, P.; Messersmith, D.; Namchuk, M.; Oh, L.; Penney, M.S.; Pierce, A.C.; Raybuck, S.A.; Rugg, A.; Salituro, F.G.; Saxena, K.; Shannon, D.; Shlyakter, D.; Swenson, L.; Tian, S.K.; Town, C.; Wang, J.; Wang, T.; Wannamaker, M.W.; Winquist, R.J.; Zuccola, H.J. Discovery of VX-509 (Decernotinib): a potent and selective Janus kinase 3 inhibitor for the treatment of autoimmune diseases. J. Med. Chem., 2015, 58, 7195-7216.
[45]
Iwata, S.; Tanaka, Y. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis. Expert Rev. Clin. Immunol., 2016, 12, 1047-1057.
[47]
Nakajima, Y.; Inoue, T.; Nakai, K.; Mukoyoshi, K.; Hamaguchi, H.; Hatanaka, K.; Sasaki, H.; Tanaka, A.; Takahashi, F.; Kunikawa, S.; Usuda, H.; Moritomo, A.; Higashi, Y.; Inami, M.; Shirakami, S. Synthesis and evaluation of novel 1H-pyrrolo [2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3. Bioorg. Med. Chem., 2015, 23, 4871-4883.
[49]
Novartis Tiergesundheit AG. Preparation of heterocyclylsubstituted
aminosulfonylmethyl cyclohexanes as Janus
kinase inhibitors. WO 2015144773, 2015.
[50]
Incyte Corporation. Preparation of piperidin-4-yl azetidine
derivatives as JAK1 inhibitors. WO 2011112662, 2011.
[51]
Clinicaltrials.gov. 20 Studies found for: INCB039110.
Available at: https://clinicaltrials.gov/ct2/results?term=INCB039110&Search=Search
[Accessed: November 24, 2017].
[52]
Bissonnette, R.; Luchi, M.; Fidelus-Gort, R.; Jackson, S.; Zhang, H.; Flores, R.; Newton, R.; Scherle, P.; Yeleswaram, S.; Chen, X.; Menter, A. A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral Janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. J. Dermatolog. Treat., 2016, 27, 332-338.
[53]
Mascarenhas, J.O.; Talpaz, M.; Gupta, V.; Foltz, L.M.; Savona, M.R.; Paquette, R.; Turner, A.R.; Coughlin, P.; Winton, E.; Burn, T.C.; O’Neill, P.; Clark, J.; Hunter, D.; Assad, A.; Hoffman, R.; Verstovsek, S. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica, 2017, 102, 327-335.
[55]
Incyte Corporation. Piperidinylcylobutyl substituted pyrrolopyridine
and pyrrolopyrimidine derivatives as JAK inhibitors.
WO 2013173720, 2013.
[56]
Merck Sharp & Dohme Corp. Preparation of pyrrolopyrimidines
as Janus kinase inhibitors. WO
2013085802, 2013.
[57]
Elwood, F.; Witter, D.J.; Piesvaux, J.; Kraybill, B.; Bays, N.; Alpert, C.; Goldenblatt, P.; Qu, Y.; Ivanovska, I.; Lee, H.H.; Chiu, C.S.; Tang, H.; Scott, M.E.; Deshmukh, S.V.; Zielstorff, M.; Byford, A.; Chakravarthy, K.; Dorosh, L.; Rivkin, A.; Klappenbach, J.; Pan, B.S.; Kariv, I.; Dinsmore, C.; Slipetz, D.; Dandliker, P.J. Evaluation of JAK3 biology in autoimmune disease using a highly selective, irreversible JAK3 inhibitor. J. Pharmacol. Exp. Ther., 2017, 361, 229-244.
[58]
Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivative as inhibitors
of Janus-related kinases (JAK) and their preparation. WO
2014128591, 2014.
[59]
Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b] pyrazinyl
and pyrrolo[2,3-d]pyridinyl acrylamides as JAK inhibitor
and their preparation. WO 2015083028, 2015.
[60]
Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b] pyrazinyl,
pyrrolo[2,3-b]pyridinyl acrylamides and epoxides
thereof. WO 2016178110, 2016.
[61]
Thorarensen, A.; Dowty, M.E.; Banker, M.E.; Juba, B.; Jussif, J.; Lin, T.; Vincent, F.; Czerwinski, R.M.; Casimiro-Garcia, A.; Unwalla, R.; Trujillo, J.I.; Liang, S.; Balbo, P.; Che, Y.; Gilbert, A.M.; Brown, M.F.; Hayward, M.; Montgomery, J.; Leung, L.; Yang, X.; Soucy, S.; Hegen, M.; Coe, J.; Langille, J.; Vajdos, F.; Chrencik, J.; Telliez, J.B. Design of a Janus kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-pyrrolo [2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans. J. Med. Chem., 2017, 60, 1971-1993.
[62]
Telliez, J.B.; Dowty, M.E.; Wang, L.; Jussif, J.; Lin, T.; Li, L.; Moy, E.; Balbo, P.; Li, W.; Zhao, Y.; Crouse, K.; Dickinson, C.; Symanowicz, P.; Hegen, M.; Banker, M.E.; Vincent, F.; Unwalla, R.; Liang, S.; Gilbert, A.M.; Brown, M.F.; Hayward, M.; Montgomery, J.; Yang, X.; Bauman, J.; Trujillo, J.I.; Casimiro-Garcia, A.; Vajdos, F.F.; Leung, L.; Geoghegan, K.F.; Quazi, A.; Xuan, D.; Jones, L.; Hett, E.; Wright, K.; Clark, J.D.; Thorarensen, A. Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition. ACS Chem. Biol., 2016, 11, 3442-3451.
[63]
Clinicaltrials.gov. 6 Studies found for: PF-06651600.
Available at:
https://clinicaltrials.gov/ct2/results?cond=&term=PF-06651600&cntry1=&state1=&recrs=
[Accessed:
November 24, 2017].
[64]
Wang, T.; Liu, X.; Hao, M.; Qiao, J.; Ju, C.; Xue, L.; Zhang, C. Design, synthesis and evaluation of pyrrolo [2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors. Bioorg. Med. Chem. Lett., 2016, 26, 2936-2941.
[65]
Lee, S.M.; Yoon, K.B.; Lee, H.J.; Kim, J.; Chung, Y.K.; Cho, W.J.; Mukai, C.; Choi, S.; Kang, K.W.; Han, S.Y.; Ko, H.; Kim, Y.C. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3. Bioorg. Med. Chem., 2016, 24, 5036-5046.
[66]
Soth, M.; Hermann, J.C.; Yee, C.; Alam, M.; Barnett, J.W.; Berry, P.; Browner, M.F.; Frank, K.; Frauchiger, S.; Harris, S.; He, Y.; Hekmat-Nejad, M.; Hendricks, T.; Henningsen, R.; Hilgenkamp, R.; Ho, H.; Hoffman, A.; Hsu, P.Y.; Hu, D.Q.; Itano, A.; Jaime-Figueroa, S.; Jahangir, A.; Jin, S.; Kuglstatter, A.; Kutach, A.K.; Liao, C.; Lynch, S.; Menke, J.; Niu, L.; Patel, V.; Railkar, A.; Roy, D.; Shao, A.; Shaw, D.; Steiner, S.; Sun, Y.; Tan, S.L.; Wang, S.; Vu, M.D. 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models. J. Med. Chem., 2013, 56, 345-356.
[67]
Jaime-Figueroa, S.; De Vicente, J.; Hermann, J.; Jahangir, A.; Jin, S.; Kuglstatter, A.; Lynch, S.M.; Menke, J.; Niu, L.; Patel, V.; Shao, A.; Soth, M.; Vu, M.D.; Yee, C. Discovery of a series of novel 5H-pyrrolo [2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors. Bioorg. Med. Chem. Lett., 2013, 23, 2522-2526.
[68]
de Vicente, J.; Lemoine, R.; Bartlett, M.; Hermann, J.C.; Hekmat-Nejad, M.; Henningsen, R.; Jin, S.; Kuglstatter, A.; Li, H.; Lovey, A.J.; Menke, J.; Niu, L.; Patel, V.; Petersen, A.; Setti, L.; Shao, A.; Tivitmahaisoon, P.; Vu, M.D.; Soth, M. Scaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazines. Bioorg. Med. Chem. Lett., 2014, 24, 4969-4975.
[69]
Duan, J.J.; Lu, Z.; Jiang, B.; Yang, B.V.; Doweyko, L.M.; Nirschl, D.S.; Haque, L.E.; Lin, S.; Brown, G.; Hynes, J., Jr; Tokarski, J.S.; Sack, J.S.; Khan, J.; Lippy, J.S.; Zhang, R.F.; Pitt, S.; Shen, G.; Pitts, W.J.; Carter, P.H.; Barrish, J.C.; Nadler, S.G.; Salter-Cid, L.M.; McKinnon, M.; Fura, A.; Schieven, G.L.; Wrobleski, S.T. Discovery of pyrrolo [1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors. Bioorg. Med. Chem. Lett., 2014, 24, 5721-5726.
[70]
Bristol-Myers Squibb Co. Pyrrolopyridazine Jak3 inhibitors
and their use for the treatment of inflammatory and autoimmune
diseases. WO 2012125886, 2012.
[72]
Jones, P.; Storer, R.I.; Sabnis, Y.A.; Wakenhut, F.M.; Whitlock, G.A.; England, K.S.; Mukaiyama, T.; Dehnhardt, C.M.; Coe, J.W.; Kortum, S.W.; Chrencik, J.E.; Brown, D.G.; Jones, R.M.; Murphy, J.R.; Yeoh, T.; Morgan, P.; Kilty, I. Design and synthesis of a pan-Janus kinase inhibitor clinical candidate (PF-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin. J. Med. Chem., 2017, 60, 767-786.
[73]
Topivert Pharma Ltd. Preparation of 4,5,6,7-tetrahydro-1Himidazo[
4,5-c]pyridine and 1,4,5,6,7,8-hexahydro-1Himidazo[
4,5-d]diazepine derivatives as Janus kinase inhibitors.
WO 2017077283, 2017.
[74]
Topivert Pharma Ltd. Preparation of 4,5,6,7-tetrahydro-1Himidazo[
4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo
[4,5-d]azepine derivatives as Janus kinase inhibitors. WO
2017077288, 2017.
[75]
Ritzén, A.; Sørensen, M.D.; Dack, K.N.; Greve, D.R.; Jerre, A.; Carnerup, M.A.; Rytved, K.A.; Bagger-Bahnsen, J. Fragment-based discovery of 6-arylindazole JAK inhibitors. ACS Med. Chem. Lett., 2016, 7, 641-646.
[78]
Merck Sharp & Dohme Corp. Cycloalkyl nitrile pyrazolo
pyridones as Janus kinase inhibitors. WO 2014146246, 2014.
[79]
Merck Sharp & Dohme Corp. Geminally substituted cyanoethylpyrazolo
pyridones as Janus kinase inhibitors. WO
2014146249, 2014.
[80]
Merck Sharp & Dohme Corp. N-(2-cyano heterocyclyl)
pyrazolo pyridones as Janus kinase inhibitors. WO
2014146492, 2014.
[81]
Merck Sharp & Dohme Corp. Acyclic cyanoethylpypyrazolo
pyridones as Janus kinase inhibitors. WO 2014146493, 2014.
[82]
Merck Sharp & Dohme Corp. Ethyl N-Boc piperidinyl
pyrazolo pyridones as Janus kinase inhibitors. 2016 WO
2016064935, 2016.
[83]
Merck Sharp & Dohme Corp. Ethyl N-Boc piperidinyl
pyrazolo pyridones as Janus kinase inhibitors. WO
2016061751, 2016.
[84]
Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines as
JAK inhibitors and their preparation. WO 2015173683, 2015.
[85]
Calitor Sciences LLC, Sunshine Lake Pharma Co., Ltd.
Preparation of substituted pyrazolo[1,5-a]pyrimidine-3-
carboxamide derivatives as JAK kinase inhibitors. WO
2015073267, 2015.
[86]
Celon Pharma S.A. Pyrazolo[1,5-a]pyrimidine derivatives
as kinase JAK-2 inhibitors. WO 2015118434, 2015.
[87]
F. Hoffmann-La Roche AG. 5-Chloro-2-
difluoromethoxyphenyl pyrazolopyrimidine compounds
which are JAK inhibitors. WO 2015177326, 2015.
[88]
Array Biopharma Inc. 4,6-Disubstituted-pyrazolo[1,5-
a]pyrazines as Janus kinase inhibitors and their preparation.
WO 2016090285, 2016.
[89]
Meyer, S.C.; Keller, M.D.; Chiu, S.; Koppikar, P.; Guryanova, O.A.; Rapaport, F.; Xu, K.; Manova, K.; Pankov, D.; O’Reilly, R.J.; Kleppe, M.; McKenney, A.S.; Shih, A.H.; Shank, K.; Ahn, J.; Papalexi, E.; Spitzer, B.; Socci, N.; Viale, A.; Mandon, E.; Ebel, N.; Andraos, R.; Rubert, J.; Dammassa, E.; Romanet, V.; Dölemeyer, A.; Zender, M.; Heinlein, M.; Rampal, R.; Weinberg, R.S.; Hoffman, R.; Sellers, W.R.; Hofmann, F.; Murakami, M.; Baffert, F.; Gaul, C.; Radimerski, T.; Levine, R.L. CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms. Cancer Cell, 2015, 28, 15-28.
[90]
Wu, S.C.; Li, L.S.; Kopp, N.; Montero, J.; Chapuy, B.; Yoda, A.; Christie, A.L.; Liu, H.; Christodoulou, A.; van Bodegom, D.; van der Zwet, J.; Layer, J.V.; Tivey, T.; Lane, A.A.; Ryan, J.A.; Ng, S.Y.; DeAngelo, D.J.; Stone, R.M.; Steensma, D.; Wadleigh, M.; Harris, M.; Mandon, E.; Ebel, N.; Andraos, R.; Romanet, V.; Dölemeyer, A.; Sterker, D.; Zender, M.; Rodig, S.J.; Murakami, M.; Hofmann, F.; Kuo, F.; Eck, M.J.; Silverman, L.B.; Sallan, S.E.; Letai, A.; Baffert, F.; Vangrevelinghe, E.; Radimerski, T.; Gaul, C.; Weinstock, D.M. Activity of the type II JAK2 inhibitor CHZ868 in B cell acute lymphoblastic leukemia. Cancer Cell, 2015, 28, 29-41.
[91]
Kim, M.K.; Shin, H.; Park, K.S.; Kim, H.; Park, J.; Kim, K.; Nam, J.; Choo, H.; Chong, Y. Benzimidazole derivatives as potent JAK1-selective inhibitors. J. Med. Chem., 2015, 58, 7596-7602.
[92]
Simov, V.; Deshmuckh, S.V.; Dinsmore, C.J.; Elwood, F.; Fernandez, R.B.; Garcia, Y.; Gibeau, C.; Gunaydin, H.; Jung, J.; Katz, J.D.; Kraybill, B.; Lapointe, B.; Patel, S.B.; Siu, T.; Su, H.; Young, J.R. Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors. Bioorg. Med. Chem. Lett., 2016, 26, 1803-1808.
[93]
JN Therapeutics. Preparation of substituted imidazo[1,2-
a]pyridin-2-ylamine compounds for treating, preventing, or
ameliorating one or more symptoms of a Janus kinasemediated
disease. WO 2016119700, 2016.
[94]
Vasbinder, M.M.; Alimzhanov, M.; Augustin, M.; Bebernitz, G.; Bell, K.; Chuaqui, C.; Deegan, T.; Ferguson, A.D.; Goodwin, K.; Huszar, D.; Kawatkar, A.; Kawatkar, S.; Read, J.; Shi, J.; Steinbacher, S.; Steuber, H.; Su, Q.; Toader, D.; Wang, H.; Woessner, R.; Wu, A.; Ye, M.; Zinda, M. Identification of azabenzimidazoles as potent JAK1 selective inhibitors. Bioorg. Med. Chem. Lett., 2016, 26, 60-67.
[95]
Galapagos NV. Imidazo[4,5-c]pyridine derivatives as JAK
kinase inhibitors useful for the treatment of degenerative and inflammatory diseases and their preparation. WO
2013117645, 2013.
[96]
Galapagos NV. Preparation of N-[4-ethyl-6-[1-
(methylsulfonyl)-3-azetidinyl]-3-pyridinyl]-N,1-dimethyl-
1H-imidazo[4,5-c]pyridin-6-amine as JAK inhibitor useful
for the treatment of degenerative and inflammatory diseases.
WO 2014111380, 2014.
[97]
Galapagos NV. Imidazo[4,5-c]pyridine derivatives useful
for the treatment of degenerative and inflammatory diseases.
WO 2013117645, 2013.
[98]
Galapagos NV. Novel compound useful for the treatment of
degenerative and inflammatory diseases. WO 2013117646, 2013.
[99]
Galapagos NV. Imidazo[4,5-c]pyridine derivatives as JAK
kinase inhibitors useful for the treatment of degenerative
and inflammatory diseases and their preparation WO
2013117649, 2013.
[100]
Galapagos NV. Preparation of pyridoimidazoles and pharmaceutical
compositions thereof for the treatment of inflammatory
disorders. WO 2017012647, 2017.
[102]
Ma, L.; Clayton, J.R.; Walgren, R.A.; Zhao, B.; Evans, R.J.; Smith, M.C.; Heinz-Taheny, K.M.; Kreklau, E.L.; Bloem, L.; Pitou, C.; Shen, W.; Strelow, J.M.; Halstead, C.; Rempala, M.E.; Parthasarathy, S.; Gillig, J.R.; Heinz, L.J.; Pei, H.; Wang, Y.; Stancato, L.F.; Dowless, M.S.; Iversen, P.W.; Burkholder, T.P. Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J., 2013, 3e109
[103]
Clinicaltrials.gov. 4 Studies found for: LY2784544.
https://clinicaltrials.gov/ct2/results?cond=&term=LY2784544&cntry1=&state1=&Search=Search
(Accessed November
24, 2017).
[104]
Celon Pharma S.A. Preparation of imidazo[1,2-b]pyridazin-
6-amine derivatives as JAK2 inhibitors. WO 2014020531, 2014.
[105]
Array Biopharma Inc. Preparation of imidazopyrimidine
derivatives for use as Jak kinase inhibitors. WO
2013055645, 2013.
[106]
Ligand Pharmaceuticals Inc. Janus kinase inhibitor compounds
and methods. WO 2013025628, 2013.
[107]
Galapagos NV. Novel compounds useful for the treatment
of degenerative and inflammatory diseases. WO
2010010190, 2010.
[108]
Menet, C.J.; Fletcher, S.R.; Van Lommen, G.; Geney, R.; Blanc, J.; Smits, K.; Jouannigot, N.; Deprez, P.; van der Aar, E.M.; Clement-Lacroix, P.; Lepescheux, L.; Galien, R.; Vayssiere, B.; Nelles, L.; Christophe, T.; Brys, R.; Uhring, M.; Ciesielski, F.; Van Rompaey, L. Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634. J. Med. Chem., 2014, 57, 9323-9342.
[109]
Danese, S.; Fiorino, G.; Peyrin-Biroulet, L. Filgotinib in Crohn’s disease: JAK is back. Gastroenterology, 2017, 153, 603-605.
[110]
Taylor, P.C.; Abdul Azeez, M.; Kiriakidis, S. Filgotinib for the treatment of rheumatoid arthritis. Expert Opin. Investig. Drugs, 2017, 26, 1181-1187.
[111]
Clinicaltrials.gov. 20 Studies found for: filgotinib.
https://clinicaltrials.gov/ct2/results?cond=&term=filgotinib&cntry1=&state1=&recrs
(Accessed November 24, 2017).
[112]
Galapagos NV. Aminotriazolopyridine for use in the treatment
of inflammation, and pharmaceutical compositions
thereof. WO 2013189771, 2013.
[113]
F. Hoffmann-La Roche AG. Preparation of triazolopyridine
compounds as Janus kinase inhibitors and methods of use
thereof. WO 2016139212, 2016.
[114]
Labadie, S.; Barrett, K.; Blair, W.S.; Chang, C.; Deshmukh, G.; Eigenbrot, C.; Gibbons, P.; Johnson, A.; Kenny, J.R.; Kohli, P.B.; Liimatta, M.; Lupardus, P.J.; Shia, S.; Steffek, M.; Ubhayakar, S.; van Abbema, A.; Zak, M. Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors. Bioorg. Med. Chem. Lett., 2013, 23, 5923-5930.
[115]
Theravance Biopharma R&D IP, LLC. Naphthyridine compounds
as Jak kinase inhibitors. WO 2016191524 2016.
[116]
Jiangsu Simcere Pharmaceutical Co., Ltd. Pyrimidine compounds
and use thereof. WO 2014075318, 2014.
[117]
Wang, Y.; Huang, W.; Xin, M.; Chen, P.; Gui, L.; Zhao, X.; Tang, F.; Wang, J.; Liu, F. Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors. Bioorg. Med. Chem., 2017, 25, 75-83.
[118]
Gehringer, M.; Pfaffenrot, E.; Bauer, S.; Laufer, S.A. Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes. ChemMedChem, 2014, 9, 277-281.
[120]
Nakamura, K.; Inami, M.; Morio, H.; Okuma, K.; Ito, M.; Noto, T.; Shirakami, S.; Hirose, J.; Morokata, T. AS2553627, a novel JAK inhibitor, prevents chronic rejection in rat cardiac allografts. Eur. J. Pharmacol., 2017, 796, 69-75.
[121]
Bristol-Myers Squibb Co. JAK2 inhibitors and their use for
the treatment of myeloproliferative diseases and cancer.
WO 2011028864, 2011.
[122]
Wan, H.; Schroeder, G.M.; Hart, A.C.; Inghrim, J.; Grebinski, J.; Tokarski, J.S.; Lorenzi, M.V.; You, D.; Mcdevitt, T.; Penhallow, B.; Vuppugalla, R.; Zhang, Y.; Gu, X.; Iyer, R.; Lombardo, L.J.; Trainor, G.L.; Ruepp, S.; Lippy, J.; Blat, Y.; Sack, J.S.; Khan, J.A.; Stefanski, K.; Sleczka, B.; Mathur, A.; Sun, J.H.; Wong, M.K.; Wu, D.R.; Li, P.; Gupta, A.; Arunachalam, P.N.; Pragalathan, B.; Narayanan, S.; Nanjundaswamy, K.C.; Kuppusamy, P.; Purandare, A.V. Discovery of a highly selective JAK2 Inhibitor, BMS-911543, for the treatment of myeloproliferative neoplasms. ACS Med. Chem. Lett., 2015, 6, 850-855.
[123]
Mace, T.A.; Shakya, R.; Elnaggar, O.; Wilson, K.; Komar, H.M.; Yang, J.; Pitarresi, J.R.; Young, G.S.; Ostrowski, M.C.; Ludwig, T.; Bekaii-Saab, T.; Bloomston, M.; Lesinski, G.B. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. Oncotarget, 2015, 6, 44509-44522.
[124]
Pomicter, A.D.; Eiring, A.M.; Senina, A.V.; Zabriskie, M.S.; Marvin, J.E.; Prchal, J.T.; O’Hare, T.; Deininger, M.W. Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm. Exp. Hematol., 2015, 43, 537-545.
[125]
Hart, A.C.; Schroeder, G.M.; Wan, H.; Grebinski, J.; Inghrim, J.; Kempson, J.; Guo, J.; Pitts, W.J.; Tokarski, J.S.; Sack, J.S.; Khan, J.A.; Lippy, J.; Lorenzi, M.V.; You, D.; McDevitt, T.; Vuppugalla, R.; Zhang, Y.; Lombardo, L.J.; Trainor, G.L.; Purandare, A.V. Structure-based design of selective Janus kinase 2 imidazo [4,5-d]pyrrolo [2,3-b]pyridine inhibitors. ACS Med. Chem. Lett., 2015, 6, 845-849.
[126]
Gehringer, M.; Forster, M.; Pfaffenrot, E.; Bauer, S.M.; Laufer, S.A. Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres. ChemMedChem, 2014, 9, 2516-2527.
[127]
F. Hoffmann-La Roche AG. Fused tricyclic compounds for
use as inhibitors of Janus kinases and their preparation. WO
2013007765, 2013.
[128]
Goedken, E.R.; Argiriadi, M.A.; Banach, D.L.; Fiamengo, B.A.; Foley, S.E.; Frank, K.E.; George, J.S.; Harris, C.M.; Hobson, A.D.; Ihle, D.C.; Marcotte, D.; Merta, P.J.; Michalak, M.E.; Murdock, S.E.; Tomlinson, M.J.; Voss, J.W. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol. J. Biol. Chem., 2015, 290, 4573-4589.
[129]
Yamagishi, H.; Shirakami, S.; Nakajima, Y.; Tanaka, A.; Takahashi, F.; Hamaguchi, H.; Hatanaka, K.; Moritomo, A.; Inami, M.; Higashi, Y.; Inoue, T. Discovery of 3,6-dihydroimidazo [4,5-d]pyrrolo [2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors. Bioorg. Med. Chem., 2015, 23, 4846-4859.
[130]
Forster, M.; Chaikuad, A.; Bauer, S.M.; Holstein, J.; Robers, M.B.; Corona, C.R.; Gehringer, M.; Pfaffenrot, E.; Ghoreschi, K.; Knapp, S.; Laufer, S.A. Sselective Jak3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket. Cell Chem. Biol., 2016, 23, 1335-1340.
[131]
Hurley, C.A.; Blair, W.S.; Bull, R.J.; Chang, C.; Crackett, P.H.; Deshmukh, G.; Dyke, H.J.; Fong, R.; Ghilardi, N.; Gibbons, P.; Hewitt, P.R.; Johnson, A.; Johnson, T.; Kenny, J.R.; Kohli, P.B.; Kulagowski, J.J.; Liimatta, M.; Lupardus, P.J.; Maxey, R.J.; Mendonca, R.; Narukulla, R.; Pulk, R.; Ubhayakar, S.; van Abbema, A.; Ward, S.I.; Waszkowycz, B.; Zak, M. Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1. Bioorg. Med. Chem. Lett., 2013, 23, 3592-3598.
[132]
Friedman, M.; Frank, K.E.; Aguirre, A.; Argiriadi, M.A.; Davis, H.; Edmunds, J.J.; George, D.M.; George, J.S.; Goedken, E.; Fiamengo, B.; Hyland, D.; Li, B.; Murtaza, A.; Morytko, M.; Somal, G.; Stewart, K.; Tarcsa, E.; Van Epps, S.; Voss, J.; Wang, L.; Woller, K.; Wishart, N. Structure activity optimization of 6H-pyrrolo [2,3-e][1,2,4]triazolo [4,3-a]pyrazines as Jak1 kinase inhibitors. Bioorg. Med. Chem. Lett., 2015, 25, 4399-4404.
[133]
F. Hoffmann-La Roche AG. Tricyclic heterocyclic compounds,
compositions and methods of use thereof as Jak inhibitors.
WO 2013007768, 2013.
[134]
Siu, T.; Kumarasinghe, S.E.; Altman, M.D.; Katcher, M.; Northrup, A.; White, C.; Rosenstein, C.; Mathur, A.; Xu, L.; Chan, G.; Bachman, E.; Bouthillette, M.; Dinsmore, C.J.; Marshall, C.G.; Young, J.R. The discovery of reverse tricyclic pyridone JAK2 inhibitors. Part 2: lead optimization. Bioorg. Med. Chem. Lett., 2014, 24, 1466-1471.
[135]
Zimmermann, K.; Sang, X.; Mastalerz, H.A.; Johnson, W.L.; Zhang, G.; Liu, Q.; Batt, D.; Lombardo, L.J.; Vyas, D.; Trainor, G.L.; Tokarski, J.S.; Lorenzi, M.V.; You, D.; Gottardis, M.M.; Lippy, J.; Khan, J.; Sack, J.S.; Purandare, A.V. 9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors. Bioorg. Med. Chem. Lett., 2015, 25, 2809-2812.
[137]
Gigante, M.; Pontrelli, P.; Herr, W.; Gigante, M.; D’Avenia, M.; Zaza, G.; Cavalcanti, E.; Accetturo, M.; Lucarelli, G.; Carrieri, G.; Battaglia, M.; Storkus, W.J.; Gesualdo, L.; Ranieri, E. miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction. J. Transl. Med., 2016, 14, 84.
Related Journals
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
Article Metrics
204
18
1